Farmakorezistentní deprese - jak dál?

Investor logo

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.
Title in English Pharmacoresistant depression – what is the next step?
Authors

ČEŠKOVÁ Eva

Year of publication 2016
Type Article in Periodical
Magazine / Source Psychiatrie pro praxi
MU Faculty or unit

Central European Institute of Technology

Citation
Web http://www.psychiatriepropraxi.cz/pdfs/psy/2016/03/03.pdf
Field Psychiatry, sexuology
Keywords pharmacoresistant depression; combination of antidepressants; augmentation; multimodal/multifunctional antide - pressants
Description Pharmacoresistant depression (treatment resistant depression, TRD) is associated with a higher suicidal risk of suicides and poor prognosis. Its management is a challenge. Before using the recommended strategies for TRD i.e. switch to another antidepressant, augmentation and combination of antidepressant, we should evaluate the diagnosis, mainly comorbidity and adequacy of previous treatment including adherence. Frequently used strategies such as augmentation and combinations have all disadvantages of polytherapy. An interesting option for TRD is monotherapy with multimodal/multifunctional antidepressants, aiming at several molecular targets with different mechanism of action. Clinical studies in this indication have not been done.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.